Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
about
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsNon-small cell lung cancer: current treatment and future advancesNon-coding RNAs in lung cancerA meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancerThe clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature reviewAssociation between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature reviewp53-Dependent anticancer effects of leptomycin B on lung adenocarcinomaAn NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancerPotential Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and CisplatinPromoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option.[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysisComputed tomography assessment of response to therapy: tumor volume change measurement, truth data, and error.Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway.Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review.Metastasis to the occipitocervical junction: A case report and review of the literature.Apoptosis block as a barrier to effective therapy in non small cell lung cancerB7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancerAnti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors.Clinicopathological significance and potential drug target of T-cadherin in NSCLC.Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus.Clinicopathological significance of CXCR4 in non-small cell lung cancer.Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of originAdvances on EGFR mutation for lung cancer.Gefitinib in non-small-cell lung cancer-an old lesson new re-visitedSquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesHow accurate are physicians in the prediction of patient survival in advanced lung cancer?The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.Surgical treatment of stage IV non-small cell lung cancer.ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancerSimilar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancerCombination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancerChemotherapeutic Response and Prognosis among Lung Cancer Patients with and without Depression.
P2860
Q21132357-D4948884-8973-43C4-8F8B-9A5FCC2FB03EQ26740333-5DE461F7-6687-4588-8701-A04F8302006FQ26866521-5F66525E-E975-4779-A8C5-A5FA941DB7CDQ26998677-506F0573-C879-4AA0-AB10-34E10C3A8594Q28068822-94A08D9F-0F26-46C6-8AC2-180E02C226A3Q28080155-4D2C66C6-416F-4E91-8382-B5E2C782073FQ28292014-DEB2AAC8-CC16-4609-99F7-319C004A47E2Q28481620-9212AAB8-8318-4762-B387-D0EE0D0EB50DQ28552029-27F4A307-4011-40A1-84E8-EA2955CB2EECQ30240147-2FC02982-181C-41AE-AAB9-2CBA05392D0EQ33373493-5D0B38AD-2FC5-4B61-A02B-1420711E97E0Q33373495-D62A1BE6-2610-4D8F-A943-AAB482B56ACCQ33399148-3FD2DD85-6169-49D4-B6C0-76F0AD49A0E4Q33430200-103849B5-B660-4EBE-BF48-D1A290C8E181Q33517101-16D7DE74-FEA6-4E65-91A2-A8ACF57B05D0Q33646091-5369B246-C875-471D-9E99-C8DC78469584Q33726181-7550794F-978B-44D9-84EF-64FD27328392Q34013035-823D0921-90F6-49C0-9CD4-FD5AD3F80C36Q34031203-E75D6AB4-002C-483F-9491-D6E05A1361E1Q34459048-AAE28F85-1B6C-48DB-A932-6C70D71227A2Q34678587-06AF3D38-EE7A-4C34-AFEB-526ADA11AF57Q34705006-133683E1-DF91-4468-8E56-9FCE3D8D68F2Q34783319-4C104A34-3460-42A2-8AE4-CB2A30E3C8E1Q34792522-5121F14E-0053-4B42-AC59-A2B868706696Q35093484-437C7AD5-0963-47DB-BDD5-EDB6B59E0950Q35171366-69AA624E-3CDD-4C2E-8A15-BC7B28AC4FE0Q35179487-372A990E-E3EF-4522-AEC0-8D593111B6A4Q35200375-30AC2698-8F8E-4B5B-9FEA-807CCA942642Q35200450-6E172E2A-4A47-44AF-AEBC-78940BF267EAQ35220347-C7835344-8DFE-44C4-A06A-8FA6181868D2Q35252885-65EB0BD7-68AC-41BE-BD19-2A6C8B11B281Q35346839-91E7CDD7-625C-4E63-A589-FB1083583D26Q35584194-4AC495BA-8895-47F1-877C-CE245983C472Q35689752-4AD4DFAE-FDC5-48B4-A76F-5692C0B986F4Q35758398-C1878C88-11DB-44F3-AF9B-D63450D16B69Q35854232-7CC906FA-700A-487A-A0BE-0C5565C39FF1Q35870217-F0977A14-8280-4406-B72B-8EA45234670FQ35972500-1252FE3B-9CB7-4BAA-A08F-70E8B3B53821Q36037013-6AA64BA1-C81B-426A-BC39-D1165EF4242BQ36190128-087F5D94-DA74-4210-815A-25EBAC78B670
P2860
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic chemotherapy for adva ...... dvances and future directions.
@en
Systemic chemotherapy for adva ...... dvances and future directions.
@nl
type
label
Systemic chemotherapy for adva ...... dvances and future directions.
@en
Systemic chemotherapy for adva ...... dvances and future directions.
@nl
prefLabel
Systemic chemotherapy for adva ...... dvances and future directions.
@en
Systemic chemotherapy for adva ...... dvances and future directions.
@nl
P1433
P1476
Systemic chemotherapy for adva ...... advances and future directions
@en
P2093
Suresh Ramalingam
P356
10.1634/THEONCOLOGIST.13-S1-5
P478
13 Suppl 1
P577
2008-01-01T00:00:00Z